CN109939016A - The composition for preventing and treating skin aging - Google Patents
The composition for preventing and treating skin aging Download PDFInfo
- Publication number
- CN109939016A CN109939016A CN201711385940.7A CN201711385940A CN109939016A CN 109939016 A CN109939016 A CN 109939016A CN 201711385940 A CN201711385940 A CN 201711385940A CN 109939016 A CN109939016 A CN 109939016A
- Authority
- CN
- China
- Prior art keywords
- composition
- cys
- argireline
- cone shell
- wrinkle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Cosmetics (AREA)
Abstract
The present invention relates to the compositions of prevention and treatment skin aging, belong to drug, cosmetic field.Technical problem to be solved by the invention is to provide the compositions of prevention and treatment skin aging, and the composition is that active constituent includes Argireline and μ-cone shell peptide product.Crowd's result on trial shows the cosmetics that the present composition is prepared into the forms such as Essence, lotion, is applied to skin, can play the effect for reducing wrinkle, easy to use, safe；Moreover, the composition works rapidly, anti-wrinkle effect is significant.Compared to the method for preventing and treating skin aging by the intrusive means such as injection creotoxin, sodium hyaluronate and collagen at present, the present invention has many advantages, such as that property easy to use, safe is good, effect is lasting, has a extensive future.
Description
Technical field
The present invention relates to the compositions of prevention and treatment skin aging, belong to drug, cosmetic field.
Background technique
The skin lines and wrinkle of face, neck and other positions are by aging, heredity, muscle movement, sunlight damage
It does harm to the resultant force with gravity and is formed, passed along with the time, generate the wrinkles of skin such as wrinkles on one's forehead, crow's feet, river word line.From
It physiologically says, the aging of skin shows the reduction of collagen and elastin laminin.Currently, the method master of prevention and treatment skin aging
Have:
1, using the cosmetics for being added to antioxidant such as plant extracts, vitamin, collagen, amino acid etc.,
But this kind of cosmetics effect is unobvious, works very slow；
2, it is treated using intrusive method:
1) botulinum toxin B otox (botulinal toxin A produced by pathogenic microbes clostridium botulinum) is injected
By inhibiting acetylcholine release to work, this toxin makes the relaxation of facial expression myoparalysis and reaches Botox
The effect of rapid anti-wrinkle, however, subcutaneous injection Botox must be carried out by doctor, at high cost, validity continues 3 to 6 months, because
This treatment must repeat, and also such as infect with very big risk, pain, inject and improper cause facial paralysis；
2) injectable collagen albumen or sodium hyaluronate fill wrinkle
Similarly, validity is only capable of continuing 3-6 months, and treatment must repeat, with high costs, and with very big risk
Such as infection, pain, injection improper cause facial paralysis；
3) the mode combination epidermal growth factor or fibroblast growth factor of micropin are applied
This mode mainly first destroys skin epidermis and then reapplies growth factor and repaired, and also belongs to intrusive mood and controls
The scope for the treatment of equally exists the risks such as infection, pain.
Since the cosmetics of existing anti aging effect, drug are respectively provided with drawbacks described above, a kind of significant effect, peace are developed
The substitute products of Quan Xingjia become a urgent problem to be solved.
Summary of the invention
The purpose of the present invention is to provide the compositions of prevention and treatment skin aging.
The present invention provides the compositions of prevention and treatment skin aging, be active constituent include Argireline and μ-cone shell peptide
Product.
Further, the weight proportion of the active constituent are as follows: Argireline: μ-cone shell peptide=(9:1)~(999:
1)。
Further, the weight proportion of the active constituent are as follows: Argireline: μ-cone shell peptide=(400:7)~
(150:1).
Further, the weight proportion of the active constituent are as follows: Argireline: μ-cone shell peptide=400:7.
Further, the μ-cone shell peptide is that amino acid sequence is
pGlu-Gly-Cys-Cys-Asn-Gly-Pro-Lys-Gly-Cys-Ser-Ser-Lys-Trp-Arg-Asp-His-
The peptide of Ala-Arg-Cys-Cys- amide, its bioactive fragment, its salt or its variant.
Further, the product is that drug, acceptable auxiliary in cosmetics is added by the active constituent of each weight proportion
Material or complementary ingredient, the external preparation being prepared.
Further, the external preparation is cosmetics.
Further, the cosmetics are Essences, lotion, freeze-dried powder, creme, gel, facial mask, foundation cream, muffin, wash one's face
Milk or aqua.
Further, the creme is face cream or eye cream.
Further, the complementary ingredient is selected from whitening agent, emollient, anti-acne agent, ultraviolet absorbing agent, skin tune
Manage ingredient one or more kinds of in agent.
The present invention provides the preparation method of the composition, include the following steps: the active constituent for taking each weight proportion,
Drug is added, in cosmetics acceptable auxiliary material or complementary ingredient to get.
The present invention provides purposes of the composition in the product of preparation prevention and treatment skin aging.
Further, the product has effects that reduce and/or desalinate skin lines, wrinkle.
Further, the product has effects that reduce and/or desalinate face, skin of neck microgroove, wrinkle.
Argireline of the present invention is [SEQ ID No:1]:
N-Acetyl-L-alpha-glutamyl-L-alpha-glutamyl-L-methionyl-L-glutaminyl-
L-arginyl-L-argininamide.No. CAS: 616204-22-9, molecular formula: C34H60N14O12S, molal weight 888g/
mol。
μ of the present invention-cone shell peptide is the mu-conotoxin peptides or its variant that patent CN104334155A is recorded.Specifically
Ground, the μ-cone shell peptide be comprising following amino acid sequence, its bioactive fragment, its salt, a combination thereof and/or its variant extremely
A kind of few mu-conotoxin peptides:
Xaa1-Xaa2-Cys-Cys-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Cys-Xaa8-Xaa9-Xaa10-Xaa11-
Cys-Xaa12-Xaa13-Xaa14-Xaa15-Xaal6-Cys-Cys-Xaa17, wherein
Xaa1 is the amino acid of any N modification,
Xaa2 is glycine,
Xaa3 is any of any acidic amino acid or its amide form thereof,
Xaa4 is glycine,
Xaa5 be proline or 3- hydroxy-proline,
Xaa6 is any basic amino acid,
Xaa7 is glycine,
Xaa8 is any non-aromatic hydroxy-amino-acid,
Xaa9 is any non-aromatic hydroxy-amino-acid,
Xaa10 is any basic amino acid,
Xaa11 is any aromatic amino acid,
Xaa12 is any basic amino acid,
Xaa13 is any of any acidic amino acid or its amide form thereof,
Xaa14 be any basic amino acid or any sulfur-containing amino acid,
Xaa15 is any hydrophobicity or nonpolar amino acid or any non-aromatic hydroxy-amino-acid,
Xaa16 is any basic amino acid,
Xaa17 is not present or is any nonpolar amino acid or amide group.
In an embodiment of the present composition, the mu-conotoxin peptides do not include by amino acid Xaa3,
At least one of the group of Xaa4, Xaa5, Xaa6 and Xaa7 composition amino acid, or any combination thereof.
In an embodiment of the present composition, the mu-conotoxin peptides do not include by amino acid Xaa8,
At least one of the group of Xaa9, Xaa10 and Xaa11 composition amino acid, or any combination thereof.
In an embodiment of the present composition, the mu-conotoxin peptides do not include by amino acid Xaa12,
At least one of the group of Xaa13, Xaa14, Xaa15 and Xaa16 composition amino acid, or any combination thereof.
In an embodiment of the present composition, the N- of the amino acid Xaa1 in the mu-conotoxin peptides is modified
Selected from including acetylation, formylated, myristoylation or amidated group；
Xaa3 and Xaa13 is independently selected from including aspartic acid (Asp), asparagine (Asn), glutamic acid (Glu), paddy ammonia
In amide (Gln) and pyroglutamic acid (pGlu or Z) group；
Xaa6, Xaa10, Xaa12 and Xaa16 are independently selected from including arginine (Arg), lysine (Lys) and histidine
(His) in group；
Xaa8 and Xaa9 is independently selected from the group comprising serine (Ser) and threonine (Thr)；
Xaa11 is selected from the group comprising phenylalanine (Phe), tyrosine (Tyr) and tryptophan (Trp)；
Xaa14, which is selected from, includes arginine (Arg), lysine (Lys) and histidine (His), cysteine (Cys) and egg ammonia
In the group of sour (Met)；
Xaa15, which is selected from, includes glycine (Gly), alanine (Ala), valine (Val), leucine (Leu) He Yiliang ammonia
Sour (Ile), serine (Ser), threonine (Thr), methionine (Met), cysteine (Cys) and proline (Pro) group in；
Xaa17, which is selected from, includes glycine (Gly), alanine (Ala), valine (Val), leucine (Leu), isoleucine
(Ile), in the group of threonine (Thr), methionine (Met), phenylalanine (Phe) and proline (Pro).
In an embodiment of the present composition, in the mu-conotoxin peptides, Xaa1 is pyroglutamic acid
(pGlu)。
Further, the μ-cone shell peptide is that amino acid sequence is
pGlu-Gly-Cys-Cys-Asn-Gly-Pro-Lys-Gly-Cys-Ser-Ser-Lys-Trp-Arg-Asp-His-
Peptide, its bioactive fragment, its salt or its variant of Ala-Ar g-Cys-Cys- amide.
Term " variant " refers to amino acid sequences different from native sequences peptide to a certain extent (i.e. by conservative
Acidic amino acid replaces and the amino acid sequence different from native sequences) peptide, thus one or more amino acid are had by another
There is the amino acid substitution of same characteristic features and conformation effect.Amino acid sequence variation is in the amino acid sequence of natural acid sequence
Certain sites have replace, missing, side chain modification and/or insertion.
The present composition can with composite emulsifier, assistant for emulsifying agent, skin conditioning agent, whitening agent, brightening agent, colorant,
Moisturizer, solubilizer, surfactant, preservative, aromatic, emollient, anti-acne agent, film forming agent, thickener, pH are adjusted
Acceptable auxiliary material in the cosmetics such as agent, buffer, stabilizer, ultraviolet absorbing agent, is prepared into aqua, lotion, Essence, face
The cosmetics such as frost, eye cream, facial mask, freeze-dried powder, gel, foundation cream, muffin, facial cleanser.
The various products of the present composition can be used for human face, neck, trick and whole skin, has and resists face
The generation in portion's (including eye), neck and other area skin microgrooves and wrinkle, and quickly desalinate microgroove and the effect of wrinkle.
Preferably, these microgrooves and wrinkle are the grooves positioned at aperture periphery, i.e., (bicker line and lip are perpendicular for nose (bridge of the nose line), oral cavity
Line), facial muscles forehead located around it (wrinkles on one's forehead, river word line), eyes (crow's feet), cheek (cheek twill), lower jaw
Deng.
The present invention provides the compositions of prevention and treatment skin aging, are prepared into the cosmetics of the forms such as Essence, lotion,
It is applied to skin, the effect for reducing wrinkle can be played, it is easy to use, safe；Moreover, the composition works rapidly, crease-resistant effect
Fruit is significant.Compared to the side for preventing and treating skin aging by the intrusive means such as injection creotoxin, sodium hyaluronate and collagen at present
Method, the present invention have many advantages, such as that property easy to use, safe is good, effect is lasting, have a extensive future.
Specific embodiment
Raw material, equipment used in the specific embodiment of the invention are known product, are obtained by purchase commercial product.
The present invention provides prevention and treatment skin aging composition, the composition be active constituent include Argireline and
μ-cone shell peptide cosmetics.
Neurotransmitter acetylcholine is to synthesize in pericaryon, and be stored in synaptic versicle, when by the external world
A kind of pair of calcium has the mucilage secretion (referred to as snare protein matter assembly) of dependence to make synaptic versicle to neuromuscular when stimulation
Synaptic zones release neurotransmitter acetylcholine, and acetylcholine stimulates muscle cell to form bioelectrical signals, bioelectrical signals
Sodium ion valve passage (people's cell expression recombination sodium channel Nav1.4) and nicotinic acetylcholine on muscle cell membrane
Channel enters muscle cell, causes contraction of muscle.Snare protein matter assembly be by three kinds of protein VAMP, Syntaxin and
What SNAP-25 was combined into.If SNARE compound disequilibrium, synaptic vesicle cannot effectively discharge acetylcholine.
In the present composition, Argireline has the function of that class creotoxin inhibits acetylcholine release, without
The cytotoxicity of Botox, its structure are similar to SNAP-25, occupy SNAP-25 in SNARE assembly with SNAP-25 competition
Position, so that the formation of SNARE is inhibited, the neurotransmitter acetyl gallbladder for releasing synaptic versicle to neuromuscular synaptic zones
Alkali is reduced.μ-cone shell peptide targets multiple voltage sensitive sodium channel, generates electrostatic interaction, blocks Nav1.4 sodium-ion channel, subtracts
Few bioelectrical signals pass through.Argireline and μ-cone shell peptide are applied in combination the present invention, and the two can rise in mechanism
To complementation, not only reduce the release of acetylcholine, but also reduce passing through for the bioelectrical signals that acetylcholine stimulation generates,
To which relaxation participates in the skin contraction that wrinkle of expressing one's feelings generate, effect of the Minimal Tension to skin is eliminated, skin lines and wrinkle are reduced.
It is observed in crowd's proof test, Argireline and μ-cone shell peptide are applied in combination the present invention, prevent and treat skin
The effect of skin aging is not the simple superposition of two kinds of ingredient effects, but can play synergistic effect.
μ used in the following embodiment-cone shell peptide amino acid sequence are as follows:
pGlu-Gly-Cys-Cys-Asn-Gly-Pro-Lys-Gly-Cys-Ser-Ser-Lys-Trp-Arg-Asp-His-
Ala-Arg-Cys-Cys- amide [SEQ ID No:2], wherein pGlu indicates pyroglutamic acid, amide expression-CONH2.It is claimed
For arginine, lysine polypeptide, No. CAS: 937286-43-6, molecular formula: C92H139N35O28S6Acetate, molal weight
2376g/mol。
The preparation of the Essence of the present invention of embodiment 1
Preparation method:
1, it is cooled to 60-70 DEG C of addition carbomer after accurately weighing water, glycerol, butanediol ebuillition of heated, stirring and dissolving is equal
It is even；
2, the carbomer in confirmation 1 is completely dissolved in uniform situation, is slowly added into Sodium Hyaluronate under stiring, is made it
It is completely dissolved, is sufficiently swollen；
3, precise PEG-75 sher butter glyceride type, double-PEG-18 methyl ether dimethylsilanes are added in 2 and stir
Uniformly；
4, it is added with stirring sodium hydroxide solution neutralization, and tests pH value, determines pH range in 5.0-7.0；
5,40 DEG C are cooled to hereinafter, stirring evenly in precise μ-cone shell peptide, Argireline addition 4；
6, it by precise and the Phenoxyethanol mixed, essence and Cremophor RH40 addition 5, stirs evenly
Discharging.
The preparation of the toner of the present invention of embodiment 2
Preparation method:
1,60-70 DEG C is cooled to after accurately weighing water, glycerol, butanediol, -26 ebuillition of heated of glycerin polyether；
2, precise PEG-75 sher butter glyceride type is added in 1 and stirs evenly；
3,40 DEG C are cooled to stir evenly hereinafter, being added in 2 under precise μ-cone shell peptide, Argireline；
4, it by precise and the Phenoxyethanol mixed, essence and Cremophor RH40 addition 3, stirs evenly
Discharging.
The preparation of the mask of the present invention of embodiment 3
Preparation method:
1,60-70 DEG C of addition card wave is cooled to after accurately weighing water, glycerol, butanediol, -26 ebuillition of heated of glycerin polyether
Nurse, stirring and dissolving are uniform；
2, the carbomer in confirmation 1 is completely dissolved in uniform situation, is slowly added into Sodium Hyaluronate under stiring, is made it
It is completely dissolved, is sufficiently swollen；
3, precise PEG-75 sher butter glyceride type is added in 2 and stirs evenly；
4, it is added with stirring sodium hydroxide solution neutralization, and tests pH value, determines pH range in 5.0-7.0；
5,40 DEG C are cooled to hereinafter, precise μ-cone shell peptide, Argireline, trehalose, biological carbohydrate gum -1, silane
Glycol salicylate is added in 4, stirs evenly；
6, by precise and the Phenoxyethanol mixed, glycerol caprylate, decoyl hydroximic acid, 1,2- pentanediol, essence
It is added in 5 with Cremophor RH40, stirs evenly discharging.
The preparation of the lotion of the present invention of embodiment 4
Preparation method:
1, C12-20 alkyl glucoside, stearine, C14-22 alcohol, PEG-100 stearate, poly- two are accurately weighed
Methylsiloxane, glycerol three (thylhexoic acid) ester, caprylic/capric triglyceride, jojoba seed oil are heated in oily phase pot
80-85 DEG C stand-by；
2, water, glycerol, butanediol, 1,2- pentanediol, carbomer are accurately weighed in water phase pot, stirring keeps material completely molten
Solution, is heated to 80-85 DEG C；
3, oily phase pot material is added in water phase pot under stiring, homogeneous 5min, cools to 45 after oil phase material adds
DEG C, μ-cone shell peptide, Argireline, Phenoxyethanol, methyl hydroxybenzoate, Nipasol, essence is added and is uniformly mixed, is added
Sodium hydroxide (10%) neutralizes, and tests pH value, determines that pH range in 5.0-7.0, stirs 10min, discharging.
The preparation of the face cream of the present invention of embodiment 5
Preparation method:
1, C20-22 alcohol phosphate, stearine, C20-22 alcohol, PEG-100 stearate, poly- diformazan are accurately weighed
Radical siloxane, glycerol three (thylhexoic acid) ester, caprylic/capric triglyceride, jojoba seed oil, Butyrospermum parkii fruit rouge are in oily phase pot
It is interior, it is heated to 80-85 DEG C for use；
2, water, glycerol, dipropylene glycol, 1,2- pentanediol, carbomer are accurately weighed in water phase pot, stirring keeps material complete
Dissolution, is heated to 80-85 DEG C；
3, oily phase pot material is added in water phase pot under stiring, homogeneous 5min, cools to 45 after oil phase material adds
DEG C, μ-cone shell peptide, Argireline, Phenoxyethanol, methyl hydroxybenzoate, Nipasol, flowers and plants essence is added and is uniformly mixed,
It is added sodium hydroxide (10%), stirs 10min, it is cooling, it is cooled to room temperature discharging.
Beneficial effects of the present invention are proved below by way of test example.
The effect of the Essence anti aging effect of the present invention of test example 1
The preparation of sample: control group, Y-A group Essence are prepared according to 1 method of embodiment respectively.
| Material name | Control group (100kg meter) | Y-A group (100kg meter) |
| Water | Add to 100kg | Add to 100kg |
| Glycerol | 4.0kg | 4.0kg |
| Butanediol | 3.0kg | 3.0kg |
| μ-cone shell peptide | — | 70mg |
| Argireline | — | 4.00g |
| PEG-75 sher butter glyceride type | 1.5kg | 1.5kg |
| Double-PEG-18 methyl ether dimethylsilanes | 1.0kg | 1.0kg |
| Phenoxyethanol | 0.4kg | 0.4kg |
| Carbomer | 0.2kg | 0.2kg |
| Sodium hydroxide (10%) | 0.6kg | 0.6kg |
| Sodium Hyaluronate | 0.1kg | 0.1kg |
| Essence | 0.06kg | 0.06kg |
| Cremophor RH40 | 0.2kg | 0.2kg |
Test method:
1, sample (Y-A sample) and reference substance containing μ-cone shell peptide and Argireline are intended for single use.
2,35 triers, half face smear Y-A sample, and half face smears reference substance, and Y-A sample and reference substance are only smeared
Once, randomized double-blind, in 2 hours, 8 hours assessment anti-wrinkle effects；Another 35 triers, full face are smeared Y-A sample, are used daily
(morning and evening) twice, 28 days assessment anti-wrinkle effects after using preceding and use.
3, two regions: crow's feet (eyes tail portion) and wrinkles on one's forehead (forehead) are assessed
4, biological assessment, fringe projection
A, main wrinkle depth
B, mean roughness
C, roughness and secondary change
D, crumple zone complete analysis is carried out for 4 to 5 wrinkles
5, clinical assessment: (by 0--100) is carried out using Bazin bulked segregant analysis in each assessment area；Each region
It grades according to the degree of wrinkle from shallow to deep according to 1 to 6.
Test result:
Table 1 changes situation using canthus fishtail line after 2 hours
Table 2 changes situation using wrinkles on one's forehead (forehead line) after 2 hours
Table 3 changes situation using canthus fishtail line after 8 hours
Table 4 changes situation using wrinkles on one's forehead (forehead line) after 8 hours
Table 5 changes situation using canthus fishtail line after 28 days
Table 6 changes situation using wrinkles on one's forehead (forehead line) after 28 days
According to the above test result it is known that Essence of the present invention reduces microgroove, wrinkle works quickly, 2 is small after use
When can receive effect, wrinkle of skin is significantly improved compared with control group；Permanence operation is more preferable, after continuous use 28 days, has
The effect of apparent desalination wrinkle, anti aging effect.
The effect of the lotion anti aging effect of the present invention of test example 2
One, the preparation of sample:
A, B, C, D group lotion are prepared respectively according to 4 method of embodiment, wherein sample A is not added with active constituent μ-cone shell
Peptide and Argireline, sample B are not added with active constituent μ-cone shell peptide, and sample C is not added with active constituent Argireline,
Sample D is added to μ-cone shell peptide and Argireline, specific formula are as follows:
Two, test method:
1, dosage grouping and given the test agent give the time
60 20-50 years old women average age 37 years old, are randomly divided into A, B, C, D group, every group of 15 people, smear respectively A, B,
C, tetra- kinds of lotions of D.0.5g is taken sooner or later daily, is uniformly applied to skin of face, continuous coating 28 days.
2, test method
Test position: right eye angle；
Testing process: face cleaning --- sitting quietly 20 minutes in laboratory --- tests (before use)
Face cleaning --- --- smearing sample 30 minutes --- test of sitting quietly 20 minutes in laboratory
Test data: before first use, 30min, for 24 hours, 7 days, 28 day datas.
Wrinkle decrease rate (%)=(using average wrinkle value after preceding average wrinkle value-sample use)/uses preceding average wrinkle
Line value * 100%.
3, laboratory apparatus: Finland Antera 3D CS (3D imaging analysis instrument).
Three, test result:
Change situation statistical result using wrinkle after lotion, see the table below:
Table 7 changes situation statistical result using wrinkle after lotion
Find out from the data of test, sample A does not have the effect that anti-aging reduces wrinkle；Sample C, D group are in 30min energy
Quick acting, wrinkle reduce by 5.01% and 5.32% respectively；Sample B, C, D using after for 24 hours, wrinkle reduces 1.52% respectively,
5.81%, 6.83%；After using 7 days, wrinkle reduces 11.63%, 8.32%, 22.14% respectively by sample B, C, D；Sample B,
C, for D after using 28 days, wrinkle reduces 15.63%, 13.27%, 32.14% respectively.
In drug combination analysis, the Q value method that Nintaus's equalization proposes is a kind of method of common evaluation drug combination effect.
Evaluating two medicines to merge effect is collaboration, superposition or antagonism, and should find out: the practical merging effect/theory of Q=is added merely expected effect
Fruit, Q use following number reflection result property: 0.85~1.15 is added to be simple, and>1.15 be collaboration, and<0.85 is antagonism (ginseng
See: Nintaus equalization estimates the second medical college of new method-" double 30 methods " Shanghai [J] journal of drug combination effect with Q value,
1985,5:353~354).
For μ-cone shell peptide and Argireline interaction in the evaluation present composition, calculate separately 7 days on probation
The Q value of wrinkle decrease rate after with 28 days:
The P value of sample B is PA, the P value of sample C is PB, the P value of sample D is PC:
7 days: P(A+B)=PA+PB- PA·PB=11.63%+8.32%-11.63% × 8.32%=18.98%
Q=PC/P(A+B)=22.14% ÷ 18.98%=1.17 ﹥ 1.15
28 days: P(A+B)=PA+PB-PA·PB=15.63%+13.27%-15.63% × 13.27%=26.83%
Q=PC/P(A+B)=32.14% ÷ 26.83%=1.20 ﹥ 1.15
Above-mentioned test result shows the D sample that μ-cone shell peptide and Argireline is used in compounding, 30min, for 24 hours, 7d, 28d
The effect for showing to reduce wrinkle illustrates combination of the present invention moreover, Q value is greater than 1.15 using wrinkle decrease rate as evaluation index
Two kinds of ingredients of μ-cone shell peptide and Argireline have played synergistic effect in terms of anti aging effect in object.
Sequence table
<110>Yin Sha cosmetics Co., Ltd
<120>composition of skin aging is prevented and treated
<130> A171517K
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 6
<212> PRT
<213>artificial sequence (Artificial Sequence)
<220>
<221> ACETYLATION
<222> (1)..(1)
<220>
<221> AMIDATION
<222> (6)..(6)
<400> 1
Glu Glu Met Gln Arg Arg
1 5
<210> 2
<211> 21
<212> PRT
<213>artificial sequence (Artificial Sequence)
<220>
<221> MOD_RES
<222> (1)..(1)
<223>Xaa=pyroglutamic acid (pGlu)
<220>
<221> AMIDATION
<222> (21)..(21)
<220>
<221> UNSURE
<222> (1)..(1)
<223> The 'Xaa' at location 1 stands for Gln, Arg, Pro, or Leu.
<400> 2
Xaa Gly Cys Cys Asn Gly Phe Lys Gly Cys Ser Ser Lys Trp Arg Asp
1 5 10 15
His Ala Arg Cys Cys
20
Claims (14)
1. the composition of skin aging is prevented and treated, it is characterized in that: be active constituent including Argireline and the production of μ-cone shell peptide
Product.
2. composition as described in claim 1, it is characterized in that: the weight proportion of the active constituent are as follows: Argireline:
μ-cone shell peptide=(9:1)~(999:1).
3. composition as claimed in claim 2, it is characterized in that: the weight proportion of the active constituent are as follows: Argireline:
μ-cone shell peptide=(400:7)~(150:1).
4. composition as claimed in claim 3, it is characterized in that: the weight proportion of the active constituent are as follows: Argireline:
μ-cone shell peptide=400:7.
5. the composition as described in Claims 1 to 4 any one, it is characterized in that: the μ-cone shell peptide is that amino acid sequence is
pGlu-Gly-Cys-Cys-Asn-Gly-Pro-Lys-Gly-Cys-Ser-Ser-Lys-Trp-Arg-Asp-His-Ala-Arg-
The peptide of Cys-Cys- amide, its bioactive fragment, its salt or its variant.
6. composition as claimed in any one of claims 1 to 5, wherein, it is characterized in that: the product is by the work of each weight proportion
Property ingredient, drug is added, acceptable auxiliary material or complementary ingredient in cosmetics, the external preparation being prepared.
7. composition as claimed in claim 6, it is characterized in that: the external preparation is cosmetics.
8. composition as claimed in claim 7, it is characterized in that: the cosmetics are Essence, lotion, freeze-dried powder, creme, Gel
Curry, facial mask, foundation cream, muffin, facial cleanser or aqua.
9. composition as claimed in claim 8, it is characterized in that: the creme is face cream or eye cream.
10. composition as claimed in claim 6, it is characterized in that: the complementary ingredient is selected from whitening agent, emollient, anti-powder
Pierce agent, ultraviolet absorbing agent, ingredient one or more kinds of in skin conditioner.
11. the preparation method of composition described in claim 1~10 any one, it is characterized in that: including the following steps: to take each heavy
Measure the active constituent of proportion, drug is added, in cosmetics acceptable auxiliary material or complementary ingredient to get.
12. purposes of the composition described in claim 1~10 any one in the product of preparation prevention and treatment skin aging.
13. purposes as claimed in claim 12, it is characterized in that: the product, which has, reduces and/or desalinate skin lines, wrinkle
The effect of.
14. purposes as claimed in claim 13, it is characterized in that: the product, which has, reduces and/or desalinate face, skin of neck
The effect of microgroove, wrinkle.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711385940.7A CN109939016A (en) | 2017-12-20 | 2017-12-20 | The composition for preventing and treating skin aging |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711385940.7A CN109939016A (en) | 2017-12-20 | 2017-12-20 | The composition for preventing and treating skin aging |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109939016A true CN109939016A (en) | 2019-06-28 |
Family
ID=67004360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711385940.7A Pending CN109939016A (en) | 2017-12-20 | 2017-12-20 | The composition for preventing and treating skin aging |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109939016A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110894225A (en) * | 2019-12-19 | 2020-03-20 | 东莞市维琪科技有限公司 | Large-scale preparation and purification method and application of mu-conopeptide |
| CN111632001A (en) * | 2020-07-02 | 2020-09-08 | 广州美兮生物科技有限公司 | Multifunctional toning lotion and preparation method thereof |
| CN112842930A (en) * | 2021-01-22 | 2021-05-28 | 广州杨森药业有限公司 | Compact anti-wrinkle composite polypeptide composition and preparation method thereof |
| CN113648235A (en) * | 2021-08-24 | 2021-11-16 | 广州优然生物科技有限公司 | Composition for instantly removing wrinkles, eye mask essence, wrinkle removing cosmetic and application |
| CN114099634A (en) * | 2020-08-26 | 2022-03-01 | C·扎维拉 | Composition and method for reducing skin wrinkles in a subject |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101365716A (en) * | 2005-11-08 | 2009-02-11 | 雅瑟里斯实验室 | Mu-conotoxin peptides and use thereof as a local anesthetic |
| CN104334155A (en) * | 2012-04-13 | 2015-02-04 | 艾克迪文 | Cosmetic composition comprising a [mu]conopeptide |
| CN105919836A (en) * | 2016-04-21 | 2016-09-07 | 珠海安和生化科技有限公司 | Anti-wrinkle composition added with plant essential oil and bioactive polypeptide and preparation method of anti-wrinkle composition |
| WO2016187012A1 (en) * | 2015-05-15 | 2016-11-24 | Biomimetic Laboratories Inc. | Formulations for treatment of skin and methods of making and using the same |
| CN107441017A (en) * | 2017-08-03 | 2017-12-08 | 佐登妮丝（广州）美容化妆品有限公司 | A kind of anti-apolexis composition and its preparation and use |
-
2017
- 2017-12-20 CN CN201711385940.7A patent/CN109939016A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101365716A (en) * | 2005-11-08 | 2009-02-11 | 雅瑟里斯实验室 | Mu-conotoxin peptides and use thereof as a local anesthetic |
| CN104334155A (en) * | 2012-04-13 | 2015-02-04 | 艾克迪文 | Cosmetic composition comprising a [mu]conopeptide |
| WO2016187012A1 (en) * | 2015-05-15 | 2016-11-24 | Biomimetic Laboratories Inc. | Formulations for treatment of skin and methods of making and using the same |
| CN105919836A (en) * | 2016-04-21 | 2016-09-07 | 珠海安和生化科技有限公司 | Anti-wrinkle composition added with plant essential oil and bioactive polypeptide and preparation method of anti-wrinkle composition |
| CN107441017A (en) * | 2017-08-03 | 2017-12-08 | 佐登妮丝（广州）美容化妆品有限公司 | A kind of anti-apolexis composition and its preparation and use |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110894225A (en) * | 2019-12-19 | 2020-03-20 | 东莞市维琪科技有限公司 | Large-scale preparation and purification method and application of mu-conopeptide |
| CN110894225B (en) * | 2019-12-19 | 2021-05-28 | 东莞市维琪科技有限公司 | Large-scale preparation and purification method and application of mu-conopeptide |
| CN111632001A (en) * | 2020-07-02 | 2020-09-08 | 广州美兮生物科技有限公司 | Multifunctional toning lotion and preparation method thereof |
| CN114099634A (en) * | 2020-08-26 | 2022-03-01 | C·扎维拉 | Composition and method for reducing skin wrinkles in a subject |
| CN112842930A (en) * | 2021-01-22 | 2021-05-28 | 广州杨森药业有限公司 | Compact anti-wrinkle composite polypeptide composition and preparation method thereof |
| CN113648235A (en) * | 2021-08-24 | 2021-11-16 | 广州优然生物科技有限公司 | Composition for instantly removing wrinkles, eye mask essence, wrinkle removing cosmetic and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109939016A (en) | The composition for preventing and treating skin aging | |
| CN106038351B (en) | It is a kind of for desalinating the peptide composition of wrinkle | |
| KR102072055B1 (en) | Cosmetic composition comprising a muconopeptide | |
| CN107106617A (en) | Include the cosmetics and/or medical composition and its use of product outside the bacterial cell from South Pole Pseudoalteromonas | |
| MX2012002424A (en) | Skin care formulations. | |
| CA2749750A1 (en) | Skin care compositions and methods of use thereof | |
| EP2555743B1 (en) | Cosmetic use of geranylgeranyl-2-propanol | |
| CN110664644B (en) | Skin care composition containing folic acid, essence and preparation method thereof | |
| CN111297727A (en) | Beautifying and plasticizing treatment composition and application thereof | |
| CN107106652A (en) | Peptide and its purposes in skin treatment | |
| CN109939026A (en) | Anti aging effect composition containing cordyceps sinensis | |
| CN108524354A (en) | Skin care compositions, facial treatment mask and preparation method thereof | |
| US10279076B2 (en) | Composition for maintaining efficacy of filler | |
| WO2013156064A1 (en) | Anti-wrinkles cosmetic composition comprising a mu-conopeptide | |
| US10463593B2 (en) | Lupin peptide extracts and skin firmness | |
| US11020337B2 (en) | Aspartyl-dipeptides for skin care and cosmetic use | |
| KR102582633B1 (en) | Cosmetic composition for skin regeneration and wrinkle improvement containing epidermal growth factor liposomes and growth factor complex | |
| CN108451790B (en) | Moisturizing essence containing hydrophilic keratin and preparation method thereof | |
| JPH0543442A (en) | Skin cosmetic | |
| CA3174981A1 (en) | Collagen compositions and methods of use thereof | |
| CN111135114A (en) | Eye cream composition for fading fine lines and preparation method thereof | |
| CN108354891A (en) | One kind is releived creams and preparation method thereof | |
| JP4993890B2 (en) | Topical skin preparation | |
| CN110974716A (en) | Composition for preventing and treating striae gravidarum | |
| KR20160025952A (en) | Cosmetic composition for treating skin trouble |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190628 |